An Update on the COGiTATE Phase II Study: Feasibility and Safety of Targeting an Optimal Cerebral Perfusion Pressure as a Patient-Tailored Therapy in Severe Traumatic Brain Injury.
Tas J, Beqiri E, van Kaam CR, Ercole A, Bellen G, Bruyninckx D, Cabeleira M, Czosnyka M, Depreitere B, Donnelly J, Fedriga M, Hutchinson PJ, Menon D, Meyfroidt G, Liberti A, Outtrim JG, Robba C, Hoedemaekers CWE, Smielewski P, Aries MJ.
Tas J, et al.
Acta Neurochir Suppl. 2021;131:143-147. doi: 10.1007/978-3-030-59436-7_29.
Acta Neurochir Suppl. 2021.
PMID: 33839835
Clinical Trial.